Ikena Oncology, Inc.
IKNA
$1.14
-$0.01-0.87%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -95.28% | -90.38% | -78.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -95.28% | -90.38% | -78.07% |
| Cost of Revenue | -53.48% | -48.06% | -33.09% | -25.26% | -19.48% |
| Gross Profit | 49.82% | 38.44% | 14.26% | -2.44% | -1.94% |
| SG&A Expenses | -9.06% | -5.00% | 13.08% | 22.35% | 19.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.20% | -35.50% | -21.35% | -14.07% | -8.75% |
| Operating Income | 36.11% | 27.66% | 6.32% | -7.76% | -8.77% |
| Income Before Tax | 40.83% | 28.17% | 4.96% | -6.39% | -6.17% |
| Income Tax Expenses | 213.33% | 193.83% | -- | -- | -- |
| Earnings from Continuing Operations | 40.50% | 27.77% | 5.06% | -6.28% | -5.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.50% | 27.77% | 5.06% | -6.28% | -5.97% |
| EBIT | 36.11% | 27.66% | 6.32% | -7.76% | -8.77% |
| EBITDA | 35.72% | 27.33% | 6.08% | -7.92% | -8.57% |
| EPS Basic | 45.18% | 37.57% | 23.37% | 15.89% | 13.65% |
| Normalized Basic EPS | 47.99% | 43.47% | 28.51% | 19.80% | 16.45% |
| EPS Diluted | 45.18% | 37.57% | 23.37% | 15.89% | 13.65% |
| Normalized Diluted EPS | 47.99% | 43.47% | 28.51% | 19.80% | 16.45% |
| Average Basic Shares Outstanding | 7.92% | 15.68% | 24.09% | 26.85% | 23.41% |
| Average Diluted Shares Outstanding | 7.92% | 15.68% | 24.09% | 26.85% | 23.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |